Moreover, BNZ is a choice drug for acute CD treatment; this drug is metabolized in the liver and may promote hepatic toxicity, which can be related to an increase in AST and ALT activities in the initial weeks of treatment [32,46], as observed in this study. This evidence concerns the gene GPT and Cowden disease.